This trial is active, not recruiting.

Condition amyotrophic lateral sclerosis
Treatment ptcco2
Sponsor Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Start date April 2009
End date June 2014
Trial size 80 participants
Trial identifier NCT00879593, ANTADIR PTcCO2/SLA


Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motoneurons, with a prevalence around 5/100.000. Respiratory muscle involvement is a major feature in ALS and remains the main prognostic factor. Timing and rate of progression of this respiratory muscle involvement is also highly variable among individuals.

Respiratory manifestations justify a careful follow up including clinical evaluation, pulmonary function tests and blood gases. Prognostic value of respiratory muscle assessment has been clearly demonstrated in ALS, although several cut off values have been published. The clinical benefit of non invasive ventilation (NIV) is well established in ALS, but the optimal criteria for its initiation remain debated .

The 1999 consensus for NIV selected classical criteria to consider NIV in patients with respiratory symptoms suggesting hypoventilation: daytime hypercapnia (PaCO2 > 45 mmHg), nocturnal SaO2 < 89 % more than 5 consecutive minutes and for progressive neuromuscular disorders (NMD) (mainly ALS), a vital capacity (VC) < 50 % pred or a PImax < 60 cmH2O.

Besides daytime clinical and PFT assessment, nocturnal evaluation is essential in ALS. The prevalence of sleep apnea ranges from 16 % to 76 %.

Transcutaneous PCO2 (tcPCO2) is an attractive technique to evaluate non invasively nocturnal hypoventilation. The technique is well validated in different settings. Its use in neuromuscular disorders (NMD) is recent. In particular one study has demonstrated a high predictive value of tcPCO2 for the development of daytime hypoventilation within 1 year. To our knowledge, this technique has not been specifically assessed in ALS. There is a potential role for nocturnal PtcCO2 monitoring in the close follow up of ALS patients. Indeed, a close respiratory follow up of ALS patients is essential to determine the optimal timing of NIV, avoiding the occurence of unexpected acute respiratory failure.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Intervention model single group assignment
Masking single blind (investigator)
Primary purpose prevention
Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.

Primary Outcomes

Nocturnal Transcutaneous PCO2
time frame: 6 months

Secondary Outcomes

Pulmonary function
time frame: 6 months

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - Amyotrophic lateral sclerosis :definite, probable or probable with EMG (Airlie House Criteria, 1998). - Forced vital capacity >70% pred. - Daytime PaCO2 <43 mmHg. - Venous HCO3- <28 mmol/L Exclusion Criteria: - Patients unable to perform pulmonary function tests or nocturnal recordings. - Coexisting significant lung disease: moderate to severe asthma or COPD - Current NIV, CPAP or oxygen therapy.

Additional Information

Official title Potential Role for Nocturnal PtcCO2 Monitoring in the Close Follow up of ALS Patients.
Principal investigator Thierry PEREZ, MD
Trial information was received from ClinicalTrials.gov and was last updated in August 2015.
Information provided to ClinicalTrials.gov by Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche.